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Abstract:  Microarray-based clinical tests have become powerful tools in the diagnosis and treatment of diseases. In con-
trast to traditional DNA-based tests that largely focus on single genes associated with rare conditions, microarray-based 
tests are ideal for the study of diseases with underlying complex genetic causes. Several microarray based tests have been 
translated into clinical practice such as MammaPrint and AmpliChip CYP450. Additional cancer-related microarray-based 
tests are either in the process of FDA review or under active development, including Tissue of Tumor Origin and Ampli-
Chip p53. All diagnostic microarray testing is ordered by physicians and tested by a Clinical Laboratories Improvement 
Amendment-certified (CLIA) reference laboratory. Recently, companies offering consumer based microarray testing have 
emerged. Individuals can order tests online and service providers deliver the results directly to the clients via a password-
protected secure website. Navigenics, 23andMe and deCODE Genetics represent pioneering companies in this field. Al-
though the progress of these microarray-based tests is extremely encouraging with the potential to revolutionize the rec-
ognition and treatment of common diseases, these tests are still in their infancy and face technical, clinical and marketing 
challenges. In this article, we review microarray-based tests which are currently approved or under review by the FDA, as 
well as the consumer-based testing. We also provide a summary of the challenges and strategic solutions in the develop-
ment and clinical use of the microarray-based tests. Finally, we present a brief outlook for the future of microarray-based 
clinical applications.  
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INTRODUCTION 
  Microarray-based clinical tests enabling the simultaneous 
detection of multiple genotypes and disease markers are ex-
pected to become a significant part of clinical diagnostic 
testing in the future, and hold promise in improving disease 
diagnosis, risk stratification, and selection and optimization 
of drug regimens [1]. Microarray-based tests are superior to 
traditional DNA-based tests or histopathologic assays be-
cause of their unique ability to simultaneously measure the 
relative expression level of a large number of clinically rele-
vant genes, or to genotype a large number of allelic variants 
at one or more loci at once. These features are essential for 
the accurate diagnosis and management of diseases with un-
derlying complex genetic causes. Recently, the “Critical Path 
to New Medical Products” by the U.S. Food and Drug Ad-
ministration (FDA Whitepaper, 2004) and the Draft Guid-
ance on In Vitro Diagnostic Multivariate Index Assays 
(IVDMIA) (Draft Guidance for Industry, Clinical Laborato-
ries, and FDA Staff, 2006) have identified genomic tech-
nologies as a crucial component in advancing medical prod-
uct development and personalized medicine [2]. 
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  Although microarray technology has led to many 
research discoveries which have laid the ground work for 
evaluating disease susceptibility, diagnoses, and prognoses 
[3-5], the translation from research to clinical utility has been 
slower than the microarray community anticipated, largely 
due to technical, clinical and marketing challenges. Several 
driving forces, including the need to diagnose common com-
plex genetic diseases and the increased application of mi-
croarray technology to drug development, drug safety and 
efficacy have pushed microarray technology to the forefront 
of clinical practice. The AmpliChip CYP450 from Roche 
and MammaPrint from Agendia are the first FDA approved 
microarray-based tests for diagnostic applications. It is pre-
dicted that application of these tests to disease diagnosis, risk 
stratification and therapeutics will trigger an exponential 
increase of other microarray-based tests in the coming years. 
CURRENT STATUS OF MICROARRAY-BASED 
TESTING 
1. Clinical Microarray Testing 
AmpliChip CYP450 Test 
  Drug effectiveness and toxicity vary substantially across 
individuals. There is increasing evidence regarding the im-
portance of genetic variation in
 influencing drug metabolism Clinical Utility of Microarrays  Current Genomics, 2008, Vol. 9, No. 7    467 
and response to therapy. DNA sequence variations in genes 
for drug metabolizing enzymes, like the Cytochrome P450 
family, have major effects on the efficacy or toxicity of a 
drug [6]. The AmpliChip CYP450 test is  the first FDA-
approved, genotyping-based diagnostic test, which analyzes 
patient genotypes for two highly polymorphic cytochrome 
P450 (CYP) genes, CYP2D6 and CYP2C19. These genes 
regulate the metabolism of approximately 25 percent of all 
prescription drugs as summarized in Table 1 [7,8]. The test 
genotypes 29 polymorphisms and mutations in the CYP2D6 
gene and two polymorphisms in the CYP2C19 gene. Based 
on a patient's CYP2D6 and CYP2C19 genotype, there are 
four predicted phenotypes: poor, intermediate, extensive or 
ultrarapid metabolizers. This information provides physi-
cians with added knowledge when determining the appropri-
ate drugs and doses, ultimately leading to improvement in 
patient outcome by reducing adverse drug reactions and im-
proving drug efficacy (Fig. 1). The AmpliChip CYP450 test 
has the potential to replace lengthy trial approaches and pro-
vide a quick and more efficient means for optimizing rele-
vant drug dosage. However, to-date, there are no published 
studies to demonstrate improved patient outcome as a result 
of the AmpliChip test.  
  As of June 1, 2007, eight laboratories offer the test in the 
United States (http://www.amplichip.us/physicians/prescrib 
ingthetest.php). Physicians prescribe the AmpliChip
® 
CYP450 Test and send 3-5 ml of patient’s blood sample 
collected in an EDTA anticoagulant (lavender cap) tube to 
one of the laboratories. The results are received within sev-
eral days after receipt of the blood sample by the lab. The 
test costs between US$600 and US$1300 and is currently not 
covered by third-party insurers. However, the test is done 
only once in a person’s lifetime and provides a permanent 
genotype record which can guide physicians in effectively 
prescribing appropriate dosages of relevant medications in 
genetically susceptible patients. 
MammaPrint
® Breast Cancer Test 
  Sixty-five percent of women diagnosed with invasive 
breast cancer have lymph node-negative disease at diagnosis 
[9]. Of these women, 85% are expected to survive and be 
free from distant metastasis for 10 years [10]. However, 
most patients are treated with relatively nonspecific cyto-
toxic chemotherapy or hormonal therapy because physicians 
are unable to identify patients who will have the greatest risk 
of recurrence and most likely to benefit from the therapy 
[11]. Thus, a major goal is to stratify patients for chemother-
apy or hormonal therapy based on the patients’ risk of recur-
rence. MammaPrint is the first FDA approved, gene expres-
sion-based prognostic test which assess patients’ risk for 
distant metastasis in women under age 61 with Stage I-II 
lymph node negative breast cancer. The test was developed 
by Agendia, a gene expression-based diagnostic company in 
Amsterdam (http://www.agendia.com/), and was approved 
by the FDA in February 2007 as an Agendia-only offered 
service. The MammaPrint test measures the expression lev-
els of 70 genes in a sample of a woman's surgically removed 
breast tumor, whose activity confers information about the 
likelihood of tumor recurrence. A specific algorithm is then 
used to produce a score that determines whether the patient 
is deemed low risk or high risk for cancer metastasis [12,13]. 
The high-risk patients may then be stratified for more ag-
gressive therapy (Fig. 2). Agendia has recently shown that 
the MammaPrint test is also useful for postmenopausal 
breast cancer patients, and thus is seeking additional FDA 
clearance to include patients over the age of 60. 
  The MammaPrint test has been validated in an independ-
ent dataset, and shown to be superior to currently available 
Table 1.  Clinically Relevant Drugs Metabolized by CYP2D6 and CYP2C19 
CYP2D6 
Beta Blockers   Antidepressants  Antipsychotics  Others 
Carvedilol  
Metoprolol  
Propafenone  
Timolo 
Amitriptyline 
Clomipramine 
Desipramine 
Imipramine 
Paroxetine 
Venlafaxine 
Haloperidol 
Risperidone 
Thiroridazine 
Atomoxetine 
Codeine 
Dextromethorphan 
Flecainide 
Mexiletine 
Ondansetron 
Tamoxifen 
Tramadol 
CYP2C19 
Proton Pump Inhibitors   Antidepressants  Anti-epileptics  Others 
Omeprazole 
Lansoprazole 
Pantoprazole 
Amitriptyline 
Clomipramine 
Diazepam 
Phenytoin 
Phenobarbitone 
Cyclophosphamide 
Progesterone 468    Current Genomics, 2008, Vol. 9, No. 7  Li et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic presentation of AmpliChip CYP450 test: from determined genotype, predicted phenotype to optimized drug dose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The outline of the MammaPrint test and subsequent treatment. Adjuvant hormonal therapy should be given to patients with estrogen-
receptor-positive disease. Clinical Utility of Microarrays  Current Genomics, 2008, Vol. 9, No. 7    469 
 
clinicopathologic prognostic indicators [14]. The benefit of 
MammaPrint in therapeutic decision-making is undergoing 
evaluation in the MINDACT trial (Microarray in Node nega-
tive Disease may Avoid Chemotherapy), which is currently 
enrolling patients in Europe (www.cancer.gov/clinical trials) 
[15]. The test is not available in the United States. Users can 
order MammaPrint Specimen Collection and Transportation 
Kits online (http://usa.agendia.com/en/ordering.html), by 
placing the tumor biopsy specimens in RNARetain, an RNA 
stabilizing solution, which was also FDA-approved for this 
function in June 2007, and then send to Agendia by FedEx. 
Results are delivered electronically within 10 days at a cost 
of $3,200.  
Pathwork™ Tissue of Origin Test 
  Making the correct diagnosis of the origin of a tumor is 
critical for selection of the appropriate treatment strategy of 
any cancer [16]. Using standard pathological techniques, it is 
estimated that up to 5 to 10% of all tumors may actually be 
misclassified [17,18], and nearly 2 to 5% of all tumors need 
to be diagnosed for their origin [19]. The Tissue of Origin 
test is a gene-expression based diagnostic assay for deter-
mining the tissue of tumor origin for poorly differentiated or 
undifferentiated tumor specimens. Based on expression lev-
els of 1550 selected and 110 control genes, the test compares 
the similarity of tumors of unknown origin to cancers from 
one of 15 tissues of known origin by using proprietary nor-
malization and classification algorithms. A similarity score is 
then assigned to each of 15 tumor types in a physician-
friendly report. A Similarity Score > 30 is considered “posi-
tive,” and a score <5 is called “negative.” Values between 5 
and 30 are designated as “no call” for that tissue (Fig. 3). 
This test is expected to aid in the diagnosis of the tissue of 
origin and help physicians select appropriate tissue-directed 
therapies. 
  The performance of the test has been validated using 477 
clinical samples in a multi-center clinical trial [20]. Four 
separate laboratories have recently tested the reproducibility 
of Tissue of Origin gene-expression signatures on 60 ar-
chived tissue specimens from poorly and undifferentiated 
tumors. Cross-laboratory comparisons showed correlation 
coefficients of 0.95 to 0.97 among measurements [21]. Tis-
sue of Origin is currently under FDA review. On April 22, 
2008, Pathwork Diagnostics announced the launch of the 
Pathwork Tissue of Origin Test through its CLIA-certified 
Laboratory using Affymetrix-based PathChip™. 
AmpliChip p53 Test  
  The tumor suppressor gene p53 is one of the most fre-
quently mutated genes in human cancer (http://www-
p53.iarc.fr/index.html). Emerging research reveals that p53 
mutations are associated with the prognosis of cancer pa-
tients and can predict response to therapy in many cancers 
[22]. Thus, the identification of p53 somatic mutations will 
be useful for predicting patient outcome and response to 
treatment. The AmpliChip p53 test is a microarray-based re-
sequencing test currently under development by Roche Mo-
lecular Diagnostics. The test is designed to detect single nu-
cleotide substitutions and 1 bp deletions in the entire coding 
region and the flanking splice sites of exons 2-11 of the p53 
gene in either formalin-fixed paraffin-embedded tissue 
(FFPE) or freshly frozen tissue [23]. The AmpliChip p53 test 
queries for the presence of sequence alterations through 
comparative analysis of the hybridization pattern of a series 
of probes to sample DNA and wild-type reference DNA. 
Compared to conventional DNA sequencing, the highly re-
dundant probe tiling approach is able to detect a significantly 
lower abundance of p53 mutations in samples which contain 
mixtures of normal and tumor tissue without the need for 
microdissection.  
  Several clinical research studies using the AmpliChip 
p53 test are underway. One such study analyzed over 700 
breast cancer FFPE samples, of which p53 mutations were 
found in ~40% of patients. From this cohort, 272 samples 
were also analyzed by single strand conformation polymor-
phism (SSCP)-sequencing. These results revealed a 94.1% 
concordance between the AmpliChip p53 test and SSCP-
sequencing. Of the 16 discordant samples (6%), it was found 
 
 
 
 
 
 
 
 
 
Fig. (3). An example of Pathwork tissue of origin test report. The test produced a similarity score of >30 for colorectal tissue and <5 for other 
tissues, indicating that the tumor was originated from colorectal. Fifteen tested tissues are listed on the left. 470    Current Genomics, 2008, Vol. 9, No. 7  Li et al. 
that these samples contained insertion mutations or had > 2-
bp deletions which the AmpliChip p53 is not designed to 
detect [24]. Another ongoing study is the investigation of the 
predictive value of the AmpliChip p53 test in a clinical trial 
of patients on capecitabine and docetaxel with or without 
trastuzumab in locally advanced breast cancer. As an initial 
step, Roche is focusing on the use of AmpliChip p53 as a 
prognostic and therapy selection test in breast cancer.  
Chromosomal Abnormality Test  
  Many clinically delineated syndromes are caused by 
chromosomal abnormalities, such as submicroscopic dele-
tions or duplications [25]. Fluorescence in situ hybridization 
(FISH) with chromosome-specific probes has been an effec-
tive tool for the diagnosis of chromosomal abnormalities. 
However, due to the limited coverage of FISH probes and 
their detection sensitivity, many pathogenic chromosomal 
aberrations are still undetected. The array-based comparative 
genomic hybridization (aCGH) has proven to be an invalu-
able tool to assess chromosomal aberrations at a higher reso- 
lution and more comprehensive coverage [26]. In fact, it has 
recently become the most commonly used, microarray-based 
test in a clinical setting. The tests broadly fall into two cate-
gories: BAC-based aCGH and oligo-based aCGH. Among 
these tests, some interrogate specific regions associated with 
known chromosomal abnormalities while others detect 
known and hitherto unknown aberrations at large. 
  Several companies offer aCGH services in diagnostic 
applications, including Combimatrix Molecular Diagnostics, 
Signature Genomic Laboratories and Gene DX. UCLA 
Clinical Microarray Core recently joins the team by provid-
ing genomic analysis on Affymetrix Genome-Wide Human 
SNP Array 6.0 platform. Driven by the clinical demands, 
new generations of aCGH platforms are rapidly evolving. On 
April 8, 2008, Combimatrix Molecular Diagnostics launched 
its new version of high-density BAC array test (BAC HD 
Scan), comprised of 2437 unique large-insert clones de-
signed to both interrogate specific regions associated with 
more than 125 known genetic disorders and enable screening 
for unknown abnormalities with an average size of 1 Mb 
(median 432 Kb) resolution across the entire genome. To 
compete for better resolution, Signature Genomic Laboratory 
has moved from their traditional BAC aCGH to Oligo 
aCGH. Recently released SignatureChipOS includes 105,000 
oligonucleotides covering every region known to be in-
volved in cytogenetic abnormalities (over 150 syndromes) 
with a maximum probe spacing of one probe every 35 kb 
throughout the genome and one probe every 10 kb in clinical 
regions. Both BAC HD Scan and SignatureChipOS empha-
size identifying clinically known abnormalities. Affymetrix 
has recently released the Genome-Wide Human SNP Array 
6.0, which includes more than 1.8 million markers on a sin-
gle array with an inter-marker distance of 696 base pairs, 
providing unprecedented power to detect even very small 
gains and losses globally. This unbiased high-density oligo 
array will allow for sensitively detecting all known abnor-
malities with defined loci of interest as well as those that 
have not been clinically established. As studies using such 
high-density oligo arrays yield a dataset that can differentiate 
benign genomic variants from those associated with a dis-
ease state, the global approach of high-density oligo aCGH 
will become a dominant player in this rapidly expanding 
diagnostics market. 
2. Consumer-Based Microarray Testing 
Navigenics Health Compass  
  Confidentiality is a substantial concern for genetic tests 
that can become part of an individual’s personal health in-
formation. There is concern that health insurance and even 
job opportunities could be jeopardized if evidence of genetic 
risk factors for disease were to become a part of a patient’s 
medical record. To address this issue, web-based genetic 
testing services are emerging. One such test is Navigenics 
Health Compass developed by Navigenics Inc (http://www. 
navigenics.com/). The Health Compass is a web-based prog-
nostic test to predict risk for 18 prevalent genetic diseases 
including diabetes, obesity, cancer and heart disease (Table 
2). Using the combined data from over 4000 scientific papers 
describing associations between single nucleotide polymor-
phisms (SNPs) and certain diseases, Navigenics identified a 
subset of SNP markers for each of the 18 diseases. Based on 
the presence or absence of specific SNPs, Navigenics devel-
oped an algorithm to estimate the risk of a healthy person 
developing a particular disease. Consumers can have the test 
performed without initial involvement of a physician inter-
mediary by ordering the test kit online, and then sending a 
sample of their saliva to Affymetrix Inc. for high-density 
SNP genotyping. Navigenics staff then perform in-depth 
analysis using the proprietary SNP-disease association in-
formation and post the results on a secure internet site, which 
the customers can login and access the data. Following the 
test, a licensed genetic counselor from Navigenics will pro-
vide free consultation by phone to interpret the test results. 
Navigenics’ medical partners will provide advice on strate-
gies to possibly reduce the risk of developing the disease. 
During the entire process, customers have full control of 
their medical information and can decide if and to whom to 
disclose the information. The test was officially launched on 
April 8
th, 2008 at a cost of $2500.  
23andMe  
  A second internet-based microarray test was launched by 
23andMe on November 19, 2007. The test combines Illu-
mina genotyping with a set of tools developed by 23andMe 
to depict each customer's personal data within the context of 
the latest scientific findings, environmental and other factors 
that contribute to variation in human traits and conditions. 
The test reports risk for 16 diseases and physical traits (Table 
2). In addition, customers can use the web-based tools to 
trace ancestry and compare DNA similarity with family 
members and friends, or compare other published genetic 
information with their own genotype. In contrast to Navigen-
ics, 23andMe puts less weight on clinical prognosis, but in-
stead provides personalized genetic information. The sample 
collection and handling procedures are similar to those re-
quired by Navigenics. The analysis is completed in two to 
four weeks and at which time customers will be able to use 
their private login to access their genome data, learn their 
risks for certain diseases, explore their ancestry, and com-
pare themselves to friends and family members. The test is 
now available for $999.  Clinical Utility of Microarrays  Current Genomics, 2008, Vol. 9, No. 7    471 
deCODE Genetics  
  Officially launched on November 16, 2007 by deCODE 
Genetics in Iceland, a pioneer in disease gene hunting, de-
CODEme is the first internet-based microarray test [27]. The 
overall concept of deCODEme is same as 23andMe, but uses 
buccal cells obtained through cheek swabbing rather than 
saliva. The deCODEme test calculates genetic risk for 18 
complex genetic diseases based on the current literature, 
reconstructs the geographical distribution of the customer’s 
ancestors and compares DNA similarity with selected family 
and friends. The test also adopts Illumina technology to sur-
vey over one million SNPs. The key features and differences 
of these 3 internet-based microarray tests are summarized in 
Table 2.  
CHALLENGES AND STRATEGIC SOLUTIONS  
  Despite the numerous research discoveries and tremen- 
dous interest in using the microarray-based tests for disease 
diagnosis and patient management, few have been translated 
into clinical practice. This inaction is attributable to techni-
cal, regulatory and marketing challenges. Table 3 summa-
rizes some of the major challenges and strategic solutions for 
the development and clinical use of the microarray-based 
tests. Here, we discuss several key marketing-related chal-
lenges. 
  One major challenge for marketing some of those micro- 
array-based tests is the lack of a solid scientific foundation. 
For example, the above discussed three customer-based 
testing interrogate only about one million SNPs (or less), 
representing the common SNPs occurring in at least 5% of 
the population, whereas rare SNPs that occur at a frequency 
of 1% are underrepresented. Given the fact that there are an 
estimated 15 million SNPs along the 3 billion bases of the 
human genome [28], the current tests are incomplete and 
biased toward detection of common variations. Furthermore, 
most of the disease-associated SNP markers identified so far 
exert relatively small effects and involve interactions with 
other genetic factors and environmental conditions which are 
still poorly defined. In addition, it is estimated that 20% of 
differences in gene activity are attributed to copy-number 
variants that are not covered by SNP variations. All these 
factors represent significant limitations and raise the ques-
tion as to whether these tests are sufficiently comprehensive 
to be accurate or worthwhile. Furthermore, even if the test 
provides some useful information, are patients going to 
change their lifestyle in order to delay or prevent the dis-
ease? If patients do modify their lifestyle, will that lead to a 
decreased risk of disease? The paucity of prevention studies 
showing the benefit of genetic testing represent a significant 
barrier to translating genetic testing to clinical practice. In an 
effort to address these challenges, on January 22, 2008 ,an 
international research consortium unveiled “The 1,000 Ge-
nomes Project” which will involve sequencing the genomes 
of at least one thousand people from around the world to 
create the most detailed and medically useful picture of hu-
man genetic variation [29]. By sequencing these 1,000 ge-
nomes, rare SNPs occurring at a 1% frequency as well as 
copy number variations will be uncovered. This ambitious 
effort will significantly alleviate the current problems asso-
ciated with incomplete and biased SNP arrays and will pro-
vide a comprehensive picture of genetic variations. Ulti-
mately this should lead to a better understanding of how 
people are predisposed to or protected from disease. With 
regards to the beneficial evidence of such tests, more coordi-
Table 2.  Comparison of Three Web-Based Microarray Tests 
Company Name  Navigenics  23andMe  deCODE Genetics 
Test Name  Health Compass    deCODEme 
Genotyping platform  Affymetrix  Illumina  Illumina 
# of SNPs interrogated  One million  0.58 million plus some proprietary SNPs  One million 
Date of service launched  April 8, 2008  Nov. 19, 2007  Nov. 16, 2007 
Sample type  Saliva  Saliva  Buccal swab 
# of predicted diseases  
& physical traits 
18(Alzheimer's disease, Breast cancer, 
Celiac disease, Colon cancer, Crohn's 
disease, Type 2 diabetes, Glaucoma, 
Graves' disease, Heart attack, Lupus, 
Macular degeneration, Multiple sclero-
sis, Obesity, Osteoarthritis, Prostate 
cancer, Psoriasis, Restless legs syn-
drome, Rheumatoid arthritis) 
16 (Breast Cancer, Crohn's Disease, Heart 
Attack, Multiple Sclerosis, Obesity, 
Prostate Cancer, Restless Legs Syndrome, 
Rheumatoid Arthritis, Type 1 Diabetes, 
Type 2 Diabetes, Venous Thromboem-
bolism, Alcohol Flush Reaction, Bitter 
Taste Perception, Earwax Type, Lactose 
Intolerance, and Muscle Performance) 
20 (Age-related Macular Degeneration, 
Asthma, Alzheimer's Disease, Atrial Fibril-
lation, Breast Cancer, Celiac Disease, Colo-
rectal Cancer, Exfoliation Glaucoma XFG, 
Crohn's Disease, Multiple Sclerosis, Myo-
cardial Infarction, Obesity, Prostate Cancer, 
Psoriasis, Restless Legs, Rheumatoid Arthri-
tis, Type 1 Diabetes, Type 2 Diabetes, eye 
color and hair color) 
Follow-up strategy  Offer free genetic consultation  Provide referrals to genetic counselors  Provide referrals to genetic counselors 
Aim of the test  Emphasis on disease prognosis 
Emphasis on providing personalized  
information 
Emphasis on providing personalized  
information 
Cost $2500  $999  $985 472    Current Genomics, 2008, Vol. 9, No. 7  Li et al. 
nated, large-scale clinical trails are needed. Agendia is ag-
gressively moving toward this direction by organizing the 
MINDACT trial to evaluate the benefit of MammaPrint in 
therapeutic decision-making. 
  Other marketing challenges include cost and confidenti-
ality. These tests currently cost between $600 and $3500. 
Health insurers are unlikely to cover the costs of these tests 
until studies prove their value and can link them to improved 
health. Given that the aforementioned scientific challenges 
are being addressed, it is likely that these tests will be cov-
ered by health insurance companies in the coming years. A 
patient’s right to privacy is another concern. Many people 
worry that the results of such tests would reveal a genetic 
risk of disease and disclosure of this information may have a 
negative impact on their health insurance and employment. 
In this regard, local governments have taken protective ac-
tions with 34 states and now having non-discrimination leg-
islation covering genetic information. A similar federal law 
has already been passed by the House, and awaits approval 
in the Senate.  
  One remaining hurdle when adopting such tests is com-
munity awareness. At this point, the population at-large is 
unfamiliar with such tests and few physicians are familiar in 
the intricacy of test interpretation and how to advise patients 
based on the results. Consequently, health care providers are 
reluctant to prescribe microarray-based tests given that they 
do not fully appreciate their value at this point. An urgent 
task ahead is to develop supporting information systems 
which offer educational and consultation programs for phy-
sicians and other health care providers as well as the general 
Table 3.  Current Challenges and Strategic Solutions for the Development and Clinical Use of Microarray-Based Tests 
Technical Challenges for the Development of Microarray-Based Tests 
Technical Challenges  Strategic Solutions 
Robust analytical performance across laboratories  
with different instrument, different lots of  
reagents and different operators. 
Develop assay-specific, tissue-specific and array platform –specific data  
normalization algorism, including identifying a suitable panel of internal  
control genes for normalization, to ensure the difference in the gene  
expression is mostly due to difference in the biology of the tissue samples. 
Reproducible measurements for the same  
subject under the same conditions 
Standardize all procedures and automate operations to minimize human intervention 
Appropriate quality control materials  
specific to microarray platforms 
Develop standardized quality control kit for different microarray platforms 
Random measurement bias associated with  
sample collection and DNA/RNA quality 
Specify detailed, internationally uniformed sample collection procedures and  
requirements for each test; to quantify and standardize the requirements for  
DNA/RNA quality (both quantity and integrity) 
Systematic measurement bias associated with study  
design, population and geographical location 
Obtain samples representative of the population for whom the test is intended.  
Offer panels that provide high detection rates for all ethnic groups  
Identifying the appropriate set of genes that maximize the 
detection power to distinguish the outcome classes of a disease  
Develop new algorism and software to effectively separate and balance  
biological information and noise. Use representative and large sample population 
Marketing Challenges for the Clinical Use of Microarray-Based Tests 
Marketing Challenges  Strategic Solutions 
Scientific foundation of the tests are based on  
current literature, which is incomplete and biased 
The 1000 Genome Project announced by the International Consortium on  
January 22, 2008 will effectively address this challenge 
Absence of a sufficient scientific evidence of  
benefit for a clinical use 
Perform clinical trails to document the benefit of the use of tests 
High cost and uncertainty about insurance coverage  Address the issue of cost by technological renovation and advancement.  
Privacy issue 
Promote the passage of anti-discriminatory legislation and offer web-based testing in which 
only patients can access and decide whether and how to distribute the information  
Difficulty to obtaining FDA approval for microarray-based tests  
FDA has fully realized the importance of such tests. The approval will be  
accelerated after establishing appropriate regulatory rules 
Lack of Healthcare providers and community ed 
ucational programs  
Implement Clinician education at all levels and invest in direct to consumer advertising  Clinical Utility of Microarrays  Current Genomics, 2008, Vol. 9, No. 7    473 
population to facilitate the adoption and use. Ultimately, 
these educational programs will display the impact of mi-
croarray-based tests in therapeutic decision making.  
FUTURE PERSPECTIVE 
  After a long journey, the year 2007 saw significant ad- 
vancements in microarray-based clinical testing. Several 
microarray-based tests have now come to fruition and en- 
tered the clinical lab, the ultimate home of microarray tech- 
nology (Table 4). Many more are under development. Tes- 
sArae LLC is actively performing a TessArray testing which 
will simultaneously detect and identify hundreds of strains of 
natural and emergent viral and bacterial pathogens; bioMé- 
rieux is working on HIV genotyping and microbial contami- 
nation testing; Skyline Diagnostics is developing a test for 
acute myeloid leukemia testing; a cancer DSA pipeline is 
being established by ALMA. On March 12, 2008, Mobidiag, 
a Finland-based biotech company, launched its first microar-
ray-based test for simultaneous identification of eight differ-
ent human herpesviruses. Guided by these early clinical 
practices and driven by the explosion of new discoveries and 
marketing demands, the next wave of microarray-based tests 
will soon be upon us. There still is, however, considerable 
work ahead before these tests can impact clinical practice to 
the magnitude their potentials would allow. 
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